Navigation Links
Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
Date:9/14/2009

nties, particularly those inherent in the process of developing and commercializing drugs. Alexza's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in Alexza's Annual Report on Form 10-K for the year ended December 31, 2008, and Alexza's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings: "If our product candidates fail to show a clinically significant benefit compared to placebo, they will not be approved for marketing" and "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them". Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Research ... "Biopharmaceutical and Vaccine Production Markets" report to ... many new therapies and vaccines - including products to ... are still huge challenges during the final stages of ... when and how to risk production capital to upscale ...
(Date:9/23/2014)... 2014 Rising health concerns, ... increasing number of foreign and domestic players in the ... India   The India ... high growth potential markets worldwide due to multiple factors ... the youth, changing food consumption patterns, increasing diabetic population, ...
(Date:9/23/2014)... SAN FRANCISCO , Sept. 23, 2014  SiteOne ... round of equity financing. Led by Sears Capital Management ... and Joe Zakrzewski , the $1.5 million financing ... inhibitor program for pain and to further develop its ... other pain indications. In conjunction with the ...
Breaking Medicine Technology:Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3
... Inc., (OTC Bulletin Board: NWCI ) a ... the second quarter ended June 30, 2010. More details ... 10-Q, filed with the Securities and Exchange Commission. ... made tremendous progress in commercializing our initial solution, QTinno™," ...
... Colo., Aug. 13 Mesa Laboratories, Inc. (Nasdaq: ... Directors has declared a regular quarterly cash dividend of ... September 15, 2010 to shareholders of record at the ... Mesa Laboratories develops, acquires, manufactures and markets electronic instruments ...
Cached Medicine Technology:NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 2NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 3NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 4NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 5NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 6NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 7NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 8NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 9NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 10
(Date:9/23/2014)... News) -- Few children who take medication for ... the rates vary six-fold across counties in the ... alone can manage symptoms for many children with ... receive behavioral therapy (psychotherapy), the Rand Corp. researchers ... than 1,500 counties across the United States that ...
(Date:9/23/2014)... who are already obese as teenagers could grow up ... peers of normal weight. So says Petter Lundborg of ... Rooth of Linneas University and Lund University, all in ... United Kingdom and the United States, and the results ... , The researchers analyzed large-scale data of 145,193 Swedish-born ...
(Date:9/23/2014)... Vancouver Electrician Contractors, Pro Ace, has recently announced ... in Vancouver, BC. The company will provide services on ... maintenance project or a large-scale new installation project, Pro ... needs of the individual commercial client. Pro Ace has ... affordable price. As a result, businesses of all sizes ...
(Date:9/23/2014)... 2014 The Sloane Clinic™, a ... and Malaysia providing advanced aesthetic dermatology and cosmetic ... its impressive skin care repertoire. Specially formulated with ... against the evil forces of aging, acne and ... this new addition is revolutionizing the way we ...
(Date:9/23/2014)... New York (PRWEB) September 23, 2014 ... in courts around the country, Bernstein Liebhard LLP reports. ... Middle District of Florida on September 19th, the Court ... a case filed in that jurisdiction on behalf of ... and other complications due to his use of Risperdal. ...
Breaking Medicine News(10 mins):Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Note to young men: Fat doesn't pay 2Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3
... are helmets,enough for motorcyclists to protect themselves., ... Randall Dale,Chipkar considers motorcycle radiation a possible "Black ... higher risk for cancer development from,electromagnetic radiation shooting ... a paradox that thousands of motorcycle riders participate,in ...
... DIEGO, Dec. 3 The C-section has hit number ... Department of Health and Human,Services. Scarring, swelling, tenderness and ... annually., C-Panty, The After Cesarean Underwear(TM) attempts to ... underwear designed with the,post-surgical concerns of a C-section in ...
... HRAL),HearAtLast Holdings, Inc. announced today that their Official ... Oswald will be,featured on three news stations in ... and features are taking place in conjunction with,the ... will be co-located in,Wal-Mart Store #3065 located at ...
... in early 2008, TARRYTOWN, N.Y., Dec. 3 ... today announced that it has,completed patient enrollment in ... EpiCept NP-1 is a patented topical cream,formulation of ... ketamine,and is intended to provide long-term relief from ...
... COVER: Inside Putin,s Circle. (Atlantic and Latin America ... Anna Nemtsova,report that Russia,s real politics happens in ... for money and influence. As Vladimir Putin prepares,to ... the clans that,control the power of the Russian ...
... doctors and respect for role of parents are key, ... The death of a child is devastating for all ... doctor. , Complicating matters, even though more than 55,000 ... care -- which focuses on the pain, symptoms and ...
Cached Medicine News:Health News:Motorcycle Radiation May Be Linked to Cancer Risk 2Health News:Finally, Easy After-Cesarean Care for the 1.3 Million C-Section Moms 2Health News:HearAtLast Spokesperson Walter Gretzky and President Robert Oswald to be Featured on Three TV Segments in Conjunction with Ottawa Store Opening 2Health News:HearAtLast Spokesperson Walter Gretzky and President Robert Oswald to be Featured on Three TV Segments in Conjunction with Ottawa Store Opening 3Health News:Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy 2Health News:Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy 3Health News:Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy 4Health News:NEWSWEEK: International Editions: Highlights and Exclusives, December 10, 2007 Issue 2Health News:NEWSWEEK: International Editions: Highlights and Exclusives, December 10, 2007 Issue 3Health News:NEWSWEEK: International Editions: Highlights and Exclusives, December 10, 2007 Issue 4Health News:NEWSWEEK: International Editions: Highlights and Exclusives, December 10, 2007 Issue 5Health News:Breaking Down Barriers to End-of-Life Care for Children 2Health News:Breaking Down Barriers to End-of-Life Care for Children 3
... The HDR disposable template is ... contamination and eliminate the need ... made with premium silicone molded ... ensures accurate needle placement while ...
A sterile, cost-effective solution to eliminating the risk of cross-contamination....
... Reusable Template is designed for use ... system for prostate brachytherapy. Please be ... software match the graphics on the ... pins protruding from lower surface which ...
... The latest introduction in the family of ... design of the stepping platform features a ... scale. The EXII steeping unit has a ... visual display of transducer position and a ...
Medicine Products: